Company intelligence / Profile preview

Ascle Therapeutics

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Ascle Therapeutics develops NK and CAR-NK cell therapies, with its most advanced program ASC-101 targeting ROBO1 in breast and other cancers at IND application stage in China, and additional ROBO1-targeted and gene-edited NK programs in preclinical or discovery stages.[3]

Therapeutic areas: OncologyNeurologyDermatology
Modalities: Cell therapyNK cell therapyCAR-NK cell therapyGene editing
Industry: Biotech

Drug pipeline

7 assets

ASC103

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Porton Advanced Solutions (Porton Advanced) – strategic partnership to promote application of NK cells in cancer prevention, beauty, and anti-aging, including development and manufacturing support for NK and CAR-NK products.[1][5]

Beyond the preview

Go deeper on Ascle Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascle Therapeutics.

Explore the full profile